The FDA has not approved a stem-cell or exosome therapy specifically for erectile dysfunction as a licensed product. Investigational MSC protocols are registered with the NIH but remain unapproved for this indication. The EMA likewise has not granted a marketed ED-specific stem-cell product. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) remain the FDA-approved first-line pharmacological treatment. Patients should distinguish investigational stem-cell protocols from unproven direct-to-consumer ED clinics, which proliferate globally and often lack regulatory oversight.
Erectile dysfunction (ED) arises from vascular insufficiency, endothelial dysfunction, smooth-muscle pathology, or neurogenic impairment — often clustering with metabolic syndrome, atherosclerosis, and diabetes. Stem-cell investigations focus on whether placental mesenchymal stem cells and exosome preparations can regenerate penile vasculature, restore endothelial nitric-oxide-dependent relaxation, and repair cavernous smooth-muscle tissue. With 35 registered trials and 5 currently recruiting, the biological rationale targets restoration of penile erectile mechanics through vascular and tissue regeneration. Early clinical data suggest potential for improving erectile function, increasing rigidity and tumescence duration, and potentially reducing pharmacological dependence on phosphodiesterase-5 inhibitors when stem-cell therapy complements standard medical management.
我是候选人吗？ → · Erectile Dysfunction: full overview → · 勃起功能障碍成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估